New treatment option for imatinib
26.03.09
Category: Scientific News
EMEA approves imatinib for patients at high risk of relapse following GIST resection
At its meeting on 16–19 March 2009, the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use gave a positive opinion on an application to extend the indication of imatinib to include the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου